# 2026-19968: FDA Okays Generics for ISTURISA Tablets

2026-19968, Determination That ISTURISA (Osilodrostat) Tablets, 10 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-09-30, effective 2026-09-30; PRIA reads it as touching household money (as of 2026-10-07).

- Canonical: https://policyrisk.com/federal-register/2026-19968
- As of: 2026-10-07
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-19968
- Title: Determination That ISTURISA (Osilodrostat) Tablets, 10 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 61849
- Published: 2026-09-30
- Effective: 2026-09-30
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-07

## In one line

FDA Okays Generics for ISTURISA Tablets

## Summary

The FDA has decided that ISTURISA (osilodrostat) 10 mg tablets were not taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions of ISTURISA, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries involved.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) has determined that ISTURISA (osilodrostat) tablets, 10 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for osilodrostat tablets, 10 mg if all other legal and regulatory requirements are met.

## Effects PRIA read

- Generic makers may seek approval: benefit, medium. The FDA determined that ISTURISA (osilodrostat) 10 mg tablets were not withdrawn for reasons of safety or effectiveness, so abbreviated new drug applications (ANDAs) that refer to ISTURISA (NDA 212801) may be approved if they meet all other legal and regulatory requirements. This determination foll…
- Product listed as discontinued for non-safety reasons: benefit, low. FDA will continue to list ISTURISA (osilodrostat) 10 mg in the Orange Book 'Discontinued Drug Product List,' which denotes products discontinued from marketing for reasons other than safety or effectiveness. The Agency reviewed records and postmarketing data and found no information indicating with…
- Possible labeling updates for ANDA applicants: mixed, low. The FDA said that if it determines ISTURISA's labeling should be revised to meet current standards, the Agency will advise ANDA applicants to submit such updated labeling when seeking approval for a generic version. ANDA approval remains contingent on meeting all other legal and regulatory requirem…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-19968 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/30/2026-19968/determination-that-isturisa-osilodrostat-tablets-10-milligrams-was-not-withdrawn-from-sale-for)
- [2026-19968 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-30/pdf/2026-19968.pdf)

## Related
- [Previous: 2026-19967, National Register of Historic Places; Notification of Pending Nominations and R…](https://policyrisk.com/federal-register/2026-19967)
- [Next: 2026-19969, Agency Information Collection Activities; Interjurisdictional Invasive Species…](https://policyrisk.com/federal-register/2026-19969)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-19968 (as of 2026-10-07).
